Monthly Archives: May 2017

http://www.lslog.com/in-the-midst-of-a-deadly-opioid-crisis-ohio-sues-drugmakers-for-marketing-fraud/In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud

In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud

In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud In a new lawsuit filed on Wednesday, Ohio’s attorney general is going after Teva, Allergan, Johnson […]

http://www.lslog.com/eli-lillys-cyramza-fuels-expansion-quest-with-positive-bladder-cancer-showing/Eli Lilly's Cyramza fuels expansion quest with positive bladder cancer showing

Eli Lilly's Cyramza fuels expansion quest with positive bladder cancer showing

Eli Lilly’s Cyramza fuels expansion quest with positive bladder cancer showing Eli Lilly’s had mixed results in its quest to expand cancer blockbuster hopeful Cyramza. But the data from its […]

http://www.lslog.com/teva-posts-positive-phase-3-migraine-data-plots-fda-submission/Teva posts positive phase 3 migraine data, plots FDA submission

Teva posts positive phase 3 migraine data, plots FDA submission

Teva posts positive phase 3 migraine data, plots FDA submission Israeli pharma Teva has hit its endpoints in the phase 3 Halo study of fremanezumab in migraines as it looks […]

http://www.lslog.com/chiltern-buys-japanese-cro-ida-boosting-its-asia-footprint/Chiltern buys Japanese CRO IDA, boosting its Asia footprint

Chiltern buys Japanese CRO IDA, boosting its Asia footprint

Chiltern buys Japanese CRO IDA, boosting its Asia footprint Chiltern has acquired Japanese CRO Integrated Development Associates (IDA), strengthening its presence in Asia. Source: FierceMedicalDevices News Chiltern buys Japanese CRO […]

http://www.lslog.com/gemphires-ceo-resigns-for-personal-reasons-plots-new-entrepreneurial-ops/Gemphire’s CEO resigns for ‘personal reasons,' plots new entrepreneurial ops

Gemphire’s CEO resigns for ‘personal reasons,' plots new entrepreneurial ops

Gemphire’s CEO resigns for ‘personal reasons,’ plots new entrepreneurial ops Gemphire’s CEO and president Mina Sooch has resigned for “personal reasons” less than a year after helping get its cut-price […]

http://www.lslog.com/swiss-biotech-nls-touts-positive-adhd-data-plots-late-stage-tests/Swiss biotech NLS touts positive ADHD data, plots late-stage tests

Swiss biotech NLS touts positive ADHD data, plots late-stage tests

Swiss biotech NLS touts positive ADHD data, plots late-stage tests NLS Pharma has posted some positive data for its ADHD candidate mazindol CR, which it hopes will have better luck […]

http://www.lslog.com/pfizers-trumenba-to-challenge-glaxosmithklines-bexsero-with-eu-nod/Pfizer’s Trumenba to challenge GlaxoSmithKline's Bexsero with EU nod

Pfizer’s Trumenba to challenge GlaxoSmithKline's Bexsero with EU nod

Pfizer’s Trumenba to challenge GlaxoSmithKline’s Bexsero with EU nod Meningococcal B vaccine Bexsero has been helping drive revenue growth for GlaxoSmithKline, but now, with a European approval, Pfizer’s Trumenba is […]

http://www.lslog.com/astrazeneca-puts-brilinta-bydureon-on-pay-for-performance-bandwagon-with-harvard-pilgrim-deals/AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon with Harvard Pilgrim deals

AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon with Harvard Pilgrim deals

AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon with Harvard Pilgrim deals Pay-for-performance deals have been gaining popularity among drugmakers eager to snag payer favor for their meds, and Harvard Pilgrim […]

http://www.lslog.com/lawsuit-says-novo-optumrx-mutually-benefited-from-rebate-scheme-while-consumers-paid-the-price/Lawsuit says Novo, OptumRx 'mutually benefited' from rebate scheme, while consumers paid the price

Lawsuit says Novo, OptumRx 'mutually benefited' from rebate scheme, while consumers paid the price

Lawsuit says Novo, OptumRx ‘mutually benefited’ from rebate scheme, while consumers paid the price Novo Nordisk is the target, along with pharmacy benefit manager OptumRX, of a new proposed class […]

http://www.lslog.com/roche-boehringer-tout-new-idiopathic-pulmonary-fibrosis-analyses-to-boost-their-rival-medications/Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since […]